Skip to Content
Merck
CN

AB748

Anti-Collagen Type IV Antibody

Chemicon®, from rabbit

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
human
Application:
ELISA, IHC
Citations:
37
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

rabbit

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable, immunohistochemistry: suitable

suitability

not suitable for immunohistochemistry (Paraffin), not suitable for Western blot

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... COL4A1(1282)

Immunogen

Purified human placental collagen type IV

Application

Anti-Collagen Type IV Antibody detects level of Collagen Type IV & has been published & validated for use in ELISA, IH.
ELISA on human collagen type IV: 1:3,000

Indirect immunofluorescent visualization of collagen type IV on cryostat sections of human tissue: 1:20-1:40, fresh frozen or acetone fixed specimens only.

Dot and slot blots: 1:300.

Not recommended for use in Western blot, or for use on paraffin-embedded tissue sections.

Optimal working dilutions must be determined by the end user.
Research Category
Cell Structure
Research Sub Category
ECM Proteins

Biochem/physiol Actions

Antibody reacts with native and heat denatured human type IV collagen. Less than 10% cross reactivity with collagen types I, III, and V, and less than 1% with human collagen II. Antiserum was passed over immobilized human blood plasma proteins, and human collagen types I, III, and V. Human plasma proteins do not interfere with binding to collagen.

Physical form

Affinity purified antibody from cross-absorbed antiserum. Liquid in PBS containing mannitol, dextran and no preservatives.
Format: Purified

Preparation Note

Maintain at -20°C in undiluted aliquots for up to 12 months from date of receipt. Avoid repeated freeze / thaw cycles.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Explore all of our products under Anti-Collagen Type IV Antibody

or

Try our Product Selector Tool to narrow your options


Storage Class

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Yonghui Ding et al.
Advanced healthcare materials, 6(11) (2017-03-25)
Pathological modification of the subendothelial extracellular matrix (ECM) has closely been associated with endothelial activation and subsequent cardiovascular disease progression. To understand regulatory mechanisms of these matrix modifications, the majority of previous efforts have focused on the modulation of either
Moa Lindgren et al.
Clinical & experimental metastasis, 38(2), 175-185 (2021-03-04)
No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising
Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo.
Damsky, CH; Fitzgerald, ML; Fisher, SJ
The Journal of Clinical Investigation null



Global Trade Item Number

SKUGTIN
AB74804053252325922